The role of therapeutic plasmapheresis in patients with hyperthyroidism

Basit Öğe Kaydı
dc.contributor.authorBaser, Ozden Ozdemir
dc.contributor.authorCetin, Zeynep
dc.contributor.authorCatak, Merve
dc.contributor.authorKoseoglu, Derya
dc.contributor.authorBerker, Dilek
dc.date.accessioned2021-11-01T15:05:14Z
dc.date.available2021-11-01T15:05:14Z
dc.date.issued2020
dc.department[Belirlenecek]
dc.description.abstractBackground: Hyperthyroidism is characterized by excess hormone secretion from the thyroid gland. Anti-thyroid drugs (ATDs), surgery, and radioactive iodine can be used in treatment. Plasmapheresis is a rapid and effective treatment option in cases where rapid euthyroidism is needed to be obtained due to complications of thyrotoxicosis and major adverse effects of ATDs. Material and method: We present patients receiving plasmapheresis to provide immediate euthyroidism due to severe hyperthyroidism, adverse effects of ATDs, or non-thyroid surgery from January 2012 to December 2016. Results: This study included 18 patients. The etiology of hyperthyroidism was TDG in seven patients, TDMNG in two, TA in two, TMNG in four, and one patient had AIT. Plasmapheresis was performed to achieve euthyroidism before surgery in two patients. The mean plasmapheresis session was 5.35. The mean number of sessions needed for patients with TDG and TDMNG was 4, whereas it was 6.5 for patients with TA and TMNG (p = 0.07). The decrease of mean free thyroxine and free triiodothyronine were 57 % and 73 %, respectively (p < 0.001). After plasmapheresis, total thyroidectomy was performed in 14 patients. Euthyroidism was achieved with RAI in one patient and with medical therapy in three patients. Conclusions: Plasmapheresis therapy is a reliable and effective treatment option for patients who cannot use ATDs because of their adverse events and those with hyperthyroidism that does not resolve with these drugs, or to achieve euthyroidism before total thyroidectomy, RAI or non-thyroid emergency surgery. However, it cannot be used widely because it is expensive and invasive.
dc.identifier.doi10.1016/j.transci.2020.102744
dc.identifier.issn1473-0502
dc.identifier.issue4en_US
dc.identifier.pmid32201205
dc.identifier.scopus2-s2.0-85081956708
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.transci.2020.102744
dc.identifier.urihttps://hdl.handle.net/11491/7183
dc.identifier.volume59en_US
dc.identifier.wosWOS:000564554400031
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofTransfusion And Apheresis Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPlasmapheresisen_US
dc.subjectHyperthyroidismen_US
dc.subjectAnti-thyroid drugsen_US
dc.titleThe role of therapeutic plasmapheresis in patients with hyperthyroidism
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu